TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22005912

Group type: COMPARATOR
Intervention: Nasal brushings from children with dust mite-allergic rhinitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal brushings from children with controlled or uncontrolled asthma
Number of subjects: 0
Study: 22006113

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 15
Study: 22006233

Group type: EXPERIMENTAL
Intervention: Injection of autologous platelet-rich fibrin matrix (PRFM) into the deep dermis and subdermis of the skin.
Number of subjects: 4
Study: 22007612

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (cilostazol + dual antiplatelet therapy)
Number of subjects: 127
Study: 22008340

Group type: EXPERIMENTAL
Intervention: Topical rThrombin applied as a hemostatic aid during surgical procedure (day 1)
Number of subjects: 30
Study: 22008947

Group type: EXPERIMENTAL
Intervention: Flicker light stimulation in POAG patients (n=47)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Flicker light stimulation in OHT patients (n=46)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Flicker light stimulation in healthy controls (n=56)
Number of subjects: 149
Study: 22009536

Group type: EXPERIMENTAL
Intervention: Acyl hydrazones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron chelators (desferrioxamine, deferasirox, ciclopirox olamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine
Number of subjects: 0
Study: 22011297

Group type: EXPERIMENTAL
Intervention: HBeAg-negativity
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Serum alpha fetoprotein (AFP) level
Number of subjects: 145

Group type: COMPARATOR
Intervention: Ablation method
Number of subjects: 145

Group type: COMPARATOR
Intervention: Serum HBV DNA titers
Number of subjects: 145
Study: 22011412

Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood (UCB) infusion
Number of subjects: 24
Study: 22011459

Group type: EXPERIMENTAL
Intervention: FDG PET/CT after one cycle of neoadjuvant chemotherapy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 78
Study: 22011635

Group type: EXPERIMENTAL
Intervention: SPOC questionnaire scores at 6 weeks postsurgery
Number of subjects: 359
Study: 22012004

Group type: EXPERIMENTAL
Intervention: Genexol-PM 240 mg/m(2) intravenously over 3 h every 3 weeks, with intra-patient dose escalation to 300 mg/m(2) allowed if no pre-specified toxicities were observed.
Number of subjects: 37
Study: 22012178

Group type: EXPERIMENTAL
Intervention: 0.5% propofol emulsion
Number of subjects: 0
Study: 22012846

Group type: EXPERIMENTAL
Intervention: Right knee pain only (n=42)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Bilateral knee pain (n=42)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No knee pain (n=42)
Number of subjects: 126
Study: 22013821

Group type: EXPERIMENTAL
Intervention: E-prescribing system with clinical decision support
Number of subjects: 21

Group type: COMPARATOR
Intervention: Paper-based prescriptions (control group)
Number of subjects: 21
Study: 22014006

Group type: EXPERIMENTAL
Intervention: Pazopanib and metronomic oral cyclophosphamide
Number of subjects: 0
Study: 22015991

Group type: EXPERIMENTAL
Intervention: Sorafenib dose escalation to 600 mg BID through cycle 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sorafenib dose re-escalation to 400 mg BID through cycle 3
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Completion of cycle 1 without dose modification or discontinuing treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Primary dose escalation through cycle 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reasons for escalation failure
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Common grade 3+ adverse events
Number of subjects: 50
Study: 22016484

Group type: EXPERIMENTAL
Intervention: Feno measurement pretreatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Feno measurement posttreatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Feno cut-off value
Number of subjects: 60
Study: 22016786

Group type: EXPERIMENTAL
Intervention: Liver transplant recipients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kidney transplant recipients (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 22018074

Group type: EXPERIMENTAL
Intervention: Daily vitamin D supplementation
Number of subjects: 0
Study: 22018679

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exenatide (10 μg BID)
Number of subjects: 0
Study: 22018706

Group type: EXPERIMENTAL
Intervention: Standard 5-line raster and high-definition (HD) 5-line raster scan modes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vertical HD scans
Number of subjects: 46
Study: 22018707

Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Corneal resistance factor (CRF)
Number of subjects: 191
Study: 22019221

Group type: EXPERIMENTAL
Intervention: Smaller arteriole-to-venule ratio (AVR)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Smaller AVR
Number of subjects: 1250
Study: 22019225

Group type: EXPERIMENTAL
Intervention: Central Retinal Artery Equivalent (CRAE)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Central Retinal Vein Equivalent (CRVE)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Arteriole-to-Venule Ratio (AVR)
Number of subjects: 1250
Study: 22019547

Group type: EXPERIMENTAL
Intervention: ADAS-Cog
Number of subjects: 181
Study: 22020850

Group type: EXPERIMENTAL
Intervention: Elite soccer training
Number of subjects: 467
Study: 22021369

Group type: EXPERIMENTAL
Intervention: Older RBC transfusion (stored for 40-42 days)
Number of subjects: 14
Study: 22021722

Group type: EXPERIMENTAL
Intervention: Amoxicillin and Clavulanic Acid (antibiotic therapy)
Number of subjects: 0
Study: 22021757

Group type: EXPERIMENTAL
Intervention: Yoga respiratory exercises (Bhastrika)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Stretching (control)
Number of subjects: 76
Study: 22021780

Group type: EXPERIMENTAL
Intervention: Early closure of temporary ileostomy (EASY)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Late reversal of temporary ileostomy (standard procedure)
Number of subjects: 200
Study: 22021788

Group type: EXPERIMENTAL
Intervention: Tight glycaemic control (intravenous, then subcutaneous insulin to control blood glucose to 4.4-6.5 mmol/l)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tight glycaemic control
Number of subjects: 20
Study: 22021870

Group type: EXPERIMENTAL
Intervention: Manual Physical Therapy (MPT) - 6 sessions
Number of subjects: 104

Group type: COMPARATOR
Intervention: Corticosteroid Injections (CSI) - 1 to 3 sessions
Number of subjects: 104
Study: 22021873

Group type: EXPERIMENTAL
Intervention: Viusid (three oral sachets daily, n=50)
Number of subjects: 100
Study: 22021883

Group type: EXPERIMENTAL
Intervention: 500 U Dysport (botulinum toxin A)
Number of subjects: 516
Study: 22021885

Group type: EXPERIMENTAL
Intervention: 10 h of on-site Road Tour training
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: 10 h of on-site Road Tour training with 4 h of booster training at 11 months postrandomisation
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: 10 h of at-home Road Tour training using the participant's personal computer
Number of subjects: 681

Group type: COMPARATOR
Intervention: 10 h of on-site attention control using computerised crossword puzzles (Boatload of Crosswords)
Number of subjects: 681
Study: 22022345

Group type: EXPERIMENTAL
Intervention: ¡Viva Bien!
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study: 22022448

Group type: COMPARATOR
Intervention: RTS,S malaria vaccine
Number of subjects: 0
Study: 22023158

Group type: EXPERIMENTAL
Intervention: Diaphragm pacing (electrical stimulation)
Number of subjects: 18
Study: 22023777

Group type: EXPERIMENTAL
Intervention: Urine sTREM-1
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Urine sTREM-1, SCr, BUN
Number of subjects: 104
Study: 22024527

Group type: EXPERIMENTAL
Intervention: Etravirine (ETR) resistance measured by Monogram weighted score (WS) and DUET WS.
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: HIV RNA ≥ 4 log₁₀ copies/ml at failure.
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) resistance-associated mutations (RAMs).
Number of subjects: 225
Study: 22024601

Group type: EXPERIMENTAL
Intervention: Pacemaker (PM) intervention
Number of subjects: 481
Study: 22025149

Group type: EXPERIMENTAL
Intervention: R1507 9 mg/kg intravenously once a week
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: R1507 27 mg/kg intravenously every three weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 115
Study: 22025151

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; external-beam radiation therapy (EBRT) 5 days a week at 1.8 Gy/d for 25 fractions
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with oxaliplatin, PI-FU, and EBRT
Number of subjects: 93
Study: 22025154

Group type: EXPERIMENTAL
Intervention: Figitumumab at 30 mg/kg intravenously every 4 weeks for a median of 2 cycles (range, 1 to 16)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Figitumumab at 30 mg/kg with baseline free IGF-1 ≥ 0.65 ng/mL
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Figitumumab at 30 mg/kg with pretreatment circulating free IGF-1 lower than 0.65 ng/mL
Number of subjects: 107
Study: 22025196

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 45 mg 6-month depot
Number of subjects: 151
Study: 22025453

Group type: EXPERIMENTAL
Intervention: DGCR8, AGO1, AGO2, PACT, TARBP1 mRNA expression levels in AK, BCC, and SCC groups
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TARBP2 mRNA expression levels in AK, BCC, and SCC groups
Number of subjects: 28
Study: 22025778

Group type: EXPERIMENTAL
Intervention: Presence of crown-like structures (CLS) in subcutaneous adipose tissue (n = 16)
Number of subjects: 36
Study: 22026962

Group type: EXPERIMENTAL
Intervention: NNRTI-based HAART (Nevirapine and Efavirenz)
Number of subjects: 107
Study: 22027439

Group type: EXPERIMENTAL
Intervention: Corrected Walking Impairment Questionnaire (WIQc)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Corrected Estimated Ambulatory Capacity by History Questionnaire (EACH-Qc)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Walking Impairment Questionnaire (WIQ)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Maximal Walking Time (MWT) on treadmill
Number of subjects: 310
Study: 22027845

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study: 22028492

Group type: EXPERIMENTAL
Intervention: L19-IL2 in combination with dacarbazine
Number of subjects: 29
Study: 22028948

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 190
Study: 22029910

Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 113

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 113
Study: 22029981

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet
Number of subjects: 50
Study: 22030215

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at a constant rate for the first 12 hours, then titrated between 0.1 and 2.5 μg/kg/h for up to 14 days.
Number of subjects: 13
Study: 22030222

Group type: EXPERIMENTAL
Intervention: Quartile 1 (lowest) of 25(OH)D concentrations
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Lowest quartile of 25(OH)D concentrations with normal waist circumference
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Lowest quartile of 25(OH)D concentrations with abdominal obesity
Number of subjects: 2429
Study: 22030252

Group type: EXPERIMENTAL
Intervention: HBP-health literacy scale (HBP-HLS)
Number of subjects: 386
Study: 22030751

Group type: COMPARATOR
Intervention: Dextrose
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, carboplatin, nanoparticle albumin-bound paclitaxel, methotrexate
Number of subjects: 17
Study: 22030975

Group type: EXPERIMENTAL
Intervention: Swallowing 14.5 ml of water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Swallowing 20 ml of water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Swallowing 100 ml of water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rest condition
Number of subjects: 0
Study: 22031059

Group type: EXPERIMENTAL
Intervention: Mesofacial, brachyfacial, and dolichofacial subjects
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Dolichofacial subjects
Number of subjects: 78

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 78
Study: 22031271

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) combined with gait training and body weight support (BWS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ground level gait training using BWS
Number of subjects: 12
Study: 22032709

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Class 1C
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Rate
Number of subjects: 1603
Study: 22032711

Group type: EXPERIMENTAL
Intervention: FFR(CT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: CCTA stenosis
Number of subjects: 103
Study: 22033282

Group type: EXPERIMENTAL
Intervention: Mocetinostat 110 mg, administered orally three times per week
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mocetinostat 85 mg, administered orally three times per week
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mocetinostat 110 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mocetinostat 85 mg
Number of subjects: 51
Study: 22033322

Group type: EXPERIMENTAL
Intervention: Temsirolimus 75 mg/m(2) administered once weekly until disease progression or intolerance
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study: 22033493

Group type: EXPERIMENTAL
Intervention: Sequential azacitidine and lenalidomide
Number of subjects: 18
Study: 22033636

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg/bid continuously and 5-fluorouracil 200 mg/sqm/daily day 1-14 every 3 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sorafenib plus 5-fluorouracil
Number of subjects: 39
Study: 22033999

Group type: EXPERIMENTAL
Intervention: Carotid arterial strain
Number of subjects: 10407

Group type: EXPERIMENTAL
Intervention: Arterial distensibility
Number of subjects: 10407

Group type: EXPERIMENTAL
Intervention: Stiffness indices
Number of subjects: 10407

Group type: EXPERIMENTAL
Intervention: Pressure-strain
Number of subjects: 10407

Group type: EXPERIMENTAL
Intervention: Young elastic moduli
Number of subjects: 10407

Group type: EXPERIMENTAL
Intervention: Arterial compliance
Number of subjects: 10407

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10407
Study: 22034223

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 232
Study: 22034233

Group type: EXPERIMENTAL
Intervention: Concurrent septoplasty during endoscopic sinus surgery (ESS) (n = 108)
Number of subjects: 221

Group type: COMPARATOR
Intervention: No septoplasty during endoscopic sinus surgery (ESS) (n = 113)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Concurrent septoplasty during endoscopic sinus surgery (ESS)
Number of subjects: 221
Study: 22035077

Group type: EXPERIMENTAL
Intervention: Pacemaker
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Pacemaker upgrade to ICD
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Device patients
Number of subjects: 406
Study: 22035417

Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan consolidation treatment after R-CHOP chemotherapy
Number of subjects: 21
Study: 22035573

Group type: EXPERIMENTAL
Intervention: Overweight/obese study group
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study: 22035648

Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy
Number of subjects: 49
Study: 22035806

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m(2)) and carboplatin (AUC=6.0-7.5) every 21 days for 3 doses, followed by radiation therapy, followed by an additional 3 cycles of paclitaxel and carboplatin (AUC=5-6)
Number of subjects: 81
Study: 22036135

Group type: EXPERIMENTAL
Intervention: HOMA-IR ≥ 2.8 (75th percentile cutoff)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Uric acid ≥ 5.0 mg/dL
Number of subjects: 262
Study: 22036634

Group type: EXPERIMENTAL
Intervention: bosutinib therapy
Number of subjects: 288
Study: 22037543

Group type: EXPERIMENTAL
Intervention: Sublingual temperature measurement
Number of subjects: 171

Group type: COMPARATOR
Intervention: Tympanic temperature measurement
Number of subjects: 171
Study: 22038032

Group type: EXPERIMENTAL
Intervention: Endonasal surgery
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 22038064

Group type: EXPERIMENTAL
Intervention: Weight loss therapy for 1 year
Number of subjects: 57
Study: 22039246

Group type: EXPERIMENTAL
Intervention: Automatic segmentation
Number of subjects: 20
Study: 22039493

Group type: EXPERIMENTAL
Intervention: BMI cut-off points for glycaemia factor
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: BMI cut-off points for lipid factor
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: BMI cut-off points for blood pressure factor
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: WC cut-off points for glycaemia factor
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: WC cut-off points for lipid factor
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: WC cut-off points for blood pressure factor
Number of subjects: 1333
Study: 22040109

Group type: EXPERIMENTAL
Intervention: BM-MNC as a cell therapy product
Number of subjects: 11

Group type: COMPARATOR
Intervention: CLI patients
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: BM-MNC
Number of subjects: 11
Study: 22043118

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation (HGNS)
Number of subjects: 21
Study: 22044606

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m(2) and carboplatin AUC 6
Number of subjects: 66
Study: 22044927

Group type: EXPERIMENTAL
Intervention: Roche high-sensitive cTnT (hs-cTnT)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Siemens cTnI-Ultra
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Abbott-Architect cTnI
Number of subjects: 401

Group type: COMPARATOR
Intervention: Standard assay (Roche cTnT)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Sensitive cTn assays
Number of subjects: 401
Study: 22045986

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of a TLR9 agonist combined with radiation
Number of subjects: 15
Study: 22046855

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (outreach via tailored letters, automated and personal phone calls, point-of-care prompts)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control group (no screening promotion intervention)
Number of subjects: 469
Study: 22047558

Group type: EXPERIMENTAL
Intervention: AP1903 (a small-molecule dimerizing drug)
Number of subjects: 5
Study: 22048109

Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine
Number of subjects: 230
Study: 22048718

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA) titrated daily for a maximum of 72 hours.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group of healthy volunteers, 14 participants.
Number of subjects: 15
Study: 22049179

Group type: EXPERIMENTAL
Intervention: E2-negative feedback on LH in AAW
Number of subjects: 23

Group type: COMPARATOR
Intervention: E2-negative feedback on LH in CW
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E2-negative feedback on FSH in AAW
Number of subjects: 23

Group type: COMPARATOR
Intervention: E2-negative feedback on FSH in CW
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E2-positive feedback on LH in AAW
Number of subjects: 23

Group type: COMPARATOR
Intervention: E2-positive feedback on LH in CW
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E2-positive feedback on FSH in AAW
Number of subjects: 23

Group type: COMPARATOR
Intervention: E2-positive feedback on FSH in CW
Number of subjects: 23
Study: 22050371

Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (LEV) at individualized doses (1,000-4,000 mg/day; 20-80 mg/kg/day for children/adolescents weighing <50 kg)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (LEV)
Number of subjects: 217
Study: 22050987

Group type: EXPERIMENTAL
Intervention: Urine albumin to creatinine ratio categories (≤ 10 mg/g, 11-29 mg/g, 30-299 mg/g, ≥ 300 mg/g)
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Urine albumin to creatinine ratio added to clinical model
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Urine albumin to creatinine ratio
Number of subjects: 1159
Study: 22051872

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 104
Study: 22051930

Group type: COMPARATOR
Intervention: Baseline ventilator settings on the first night
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adjusted ventilator settings under PSG on the second night
Number of subjects: 8
Study: 22052198

Group type: EXPERIMENTAL
Intervention: Protocol-driven treatment (fixed metformin and glargine, insulin adjusted according to sliding scale)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard glycaemic management
Number of subjects: 99